Assessment of current clinical practices for major depression in Japan using a web-based questionnaire

QR Code

Assessment of current clinical practices for major depression in Japan using a web-based questionnaire

Hikaru Hori,1 Kentaro Yamato2 1Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan; 2JPBU Department of Medical Affairs, Takeda Pharmaceutical Co. Ltd., Tokyo, JapanCorrespondence: Kentaro YamatoJPBU Department of Medical Affairs, Takeda Pharmace...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Hori H, Yamato K
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2019
Sujets:	Japan survey diagnosis management major depression disorder Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/641d4aef8b5f45edb4bee52d6892bde2
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Pioglitazone could induce remission in major depression: a meta-analysis
par: Colle R, et autres
Publié: (2016)

Taiwanese Depression Questionnaire and AD8 Questionnaire for Screening Late-Life Depression in Communities
par: Wei YC, et autres
Publié: (2021)

Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder
par: Lam RW, et autres
Publié: (2018)

Prevalence of major depressive disorder among hemodialysis patients compared with healthy people in Japan using the Structured Clinical Interview for DSM-IV
par: Tomita T, et autres
Publié: (2016)

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
par: Yoshimura R, et autres
Publié: (2017)

Functional impairment in patients with major depressive disorder: the 2-year PERFORM study
par: Hammer-Helmich L, et autres
Publié: (2018)

Prevalence of Comorbid Anxiety Disorders and Their Associated Factors in Patients with Bipolar Disorder or Major Depressive Disorder
par: Inoue T, et autres
Publié: (2020)

Evaluation of cognitive impairment in patients with major depressive disorder in remission
par: Mustafa Ali, et autres
Publié: (2021)

Sex differences in gut microbiota in patients with major depressive disorder
par: Chen JJ, et autres
Publié: (2018)

Quality of life in euthymic patients with unipolar major depressive disorder and bipolar disorder
par: Bo Q, et autres
Publié: (2019)

Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives
par: Askalsky P, et autres
Publié: (2019)

Plasma complement component 4 increases in patients with major depressive disorder
par: Wei J, et autres
Publié: (2017)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
par: Harada E, et autres
Publié: (2016)

Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
par: McIntyre RS, et autres
Publié: (2021)

The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
par: Li G, et autres
Publié: (2016)

Elevated peripheral blood glutamate levels in major depressive disorder
par: Inoshita M, et autres
Publié: (2018)

Atrophic Corpus Callosum Associated with Altered Functional Asymmetry in Major Depressive Disorder
par: Ran S, et autres
Publié: (2020)

Biomarkers for depression: recent insights, current challenges and future prospects
par: Strawbridge R, et autres
Publié: (2017)

Predictors of Major Depressive Disorder in Older People
par: Susana Sousa, et autres
Publié: (2021)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
par: Huang Q, et autres
Publié: (2016)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
par: Kishi T, et autres
Publié: (2017)

Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data
par: Solem CT, et autres
Publié: (2016)

Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
par: Harada E, et autres
Publié: (2017)

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
par: Saragoussi D, et autres
Publié: (2018)

The level of IL-6 was associated with sleep disturbances in patients with major depressive disorder
par: Wang M, et autres
Publié: (2019)

Modulatory interactions of resting-state brain functional connectivity in major depressive disorder
par: Tu Z, et autres
Publié: (2018)

Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder
par: Tsutsumi T, et autres
Publié: (2016)

Self-stigma in borderline personality disorder – cross-sectional comparison with schizophrenia spectrum disorder, major depressive disorder, and anxiety disorders
par: Grambal A, et autres
Publié: (2016)

Management of Treatment-Resistant Depression: Challenges and Strategies
par: Voineskos D, et autres
Publié: (2020)

Plasma disturbance of phospholipid metabolism in major depressive disorder by integration of proteomics and metabolomics
par: Gui SW, et autres
Publié: (2018)

Validity of the Shahin Mixed Depression Scale: A Self-Rated Instrument Designed to Measure the Non-DSM Mixed Features in Depression
par: Shahin I, et autres
Publié: (2020)

Disrupted Brain Entropy And Functional Connectivity Patterns Of Thalamic Subregions In Major Depressive Disorder
par: Xue SW, et autres
Publié: (2019)

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan
par: Watanabe Y, et autres
Publié: (2018)

Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study
par: Saragoussi D, et autres
Publié: (2017)

Serum Exosome-Derived miR-139-5p as a Potential Biomarker for Major Depressive Disorder
par: Liang JQ, et autres
Publié: (2020)

Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
par: Jiang KD, et autres
Publié: (2017)

Victimization In Childhood Affects Depression In Adulthood Via Neuroticism: A Path Analysis Study
par: Tachi S, et autres
Publié: (2019)

Cognitive impairment in depression: recent advances and novel treatments
par: Perini G, et autres
Publié: (2019)

The Association Between Hypoxia Improvement and Electroconvulsive Therapy for Major Depressive Disorder
par: Bian Z, et autres
Publié: (2021)

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
par: Otsubo T, et autres
Publié: (2018)